Effects of Prandial Versus Fasting Glycemia on Cardiovascular Outcomes in Type 2 Diabetes: The HEART2D trial
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
OBJECTIVE—Hyperglycemia and Its Effect After Acute Myocardial Infarction on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus (HEART2D) is a multinational, randomized, controlled trial designed to compare the effects of prandial versus fasting glycemic control on risk for cardiovascular outcomes in patients with type 2 diabetes after acute myocardial infarction (AMI). RESEARCH DESIGN AND METHODS—Patients (type 2 diabetes, aged 30–75 years) were randomly assigned within 21 days after AMI to the 1) prandial strategy (PRANDIAL) (three premeal doses of insulin lispro targeting 2-h postprandial blood glucose <7.5 mmol/l) or the 2) basal strategy (BASAL) (NPH twice daily or insulin glargine once daily targeting fasting/premeal blood glucose <6.7 mmol/l). RESULTS—A total of 1,115 patients were randomly assigned (PRANDIAL n = 557; BASAL n = 558), and the mean patient participation after randomization was 963 days (range 1–1,687 days). The trial was stopped for lack of efficacy. Risks of first combined adjudicated primary cardiovascular events in the PRANDIAL (n = 174, 31.2%) and BASAL (n = 181, 32.4%) groups were similar (hazard ratio 0.98 [95% CI 0.8–1.21]). Mean A1C did not differ between the PRANDIAL and BASAL groups (7.7 ± 0.1 vs. 7.8 ± 0.1%; P = 0.4) during the study. The PRANDIAL group showed a lower daily mean postprandial blood glucose (7.8 vs. 8.6 mmol/l; P < 0.01) and 2-h postprandial blood glucose excursion (0.1 vs. 1.3 mmol/l; P < 0.001) versus the BASAL group. The BASAL group showed lower mean fasting blood glucose (7.0 vs. 8.1 mmol/l; P < 0.001) and similar daily fasting/premeal blood glucose (7.7 vs. 7.3 mmol/l; P = 0.233) versus the PRANDIAL group. CONCLUSIONS—Treating diabetic survivors of AMI with prandial versus basal strategies achieved differences in fasting blood glucose, less-than-expected differences in postprandial blood glucose, similar levels of A1C, and no difference in risk for future cardiovascular event rates.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Elevated postchallenge (2-h oral glucose tolerance test) glucose values have been associated with increased cardiovascular risk independent of fasting plasma glucose in some epidemiologic studies, whereas intervention trials have not shown postprandial glucose to be a cardiovascular risk factor independent of A1C.”
From 6. Glycemic Targets: Standards of Care in Diabetes—2023 (2023) · cites this paper as [73]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Most of the large outcome trials conducted so far have been mostly based on preprandial glucose and A1C targets, with limited evidence of a long-term benefit of targeting PPG alone (49,50).”
From Targets for Glycemic Control (2018) · cites this paper as [50]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“However, manipulating prandial glucose levels failed to impact clinical outcome, and therefore, this remains an unresolved area.142,143”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [143]
The cited source says what the claim attributes to it.
In the citing paper
“Additionally, a randomized controlled trial in patients with known CVD found no CVD benefit of insulin treatment plans targeting postprandial glucose compared with those targeting preprandial glucose (73).”
From 6. Glycemic Targets: Standards of Care in Diabetes—2023 (2023) · cites this paper as [73]
The cited source says what the claim attributes to it.
In the citing paper
“Elevated postchallenge (2-h oral glucose tolerance test) glucose values have been associated with increased cardiovascular risk independent of fasting plasma glucose in some epidemiologic studies, whereas intervention trials have not shown postprandial glucose to be a cardiovascular risk factor independent of A1C.”
From 6. Glycemic Targets: Standards of Care in Diabetes—2023 (2023) · cites this paper as [73]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stratton, I. M. (2000) · BMJ · doi:10.1136/bmj.321.7258.405 · Cited by 9,059
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Haffner, S. M., Lehto, S., Rönnemaa, T., Pyörälä, K., & Laakso, M. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807233390404 · Cited by 7,000
The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men
Lakka, H.-M. (2002) · JAMA · doi:10.1001/jama.288.21.2709 · Cited by 5,033
Glucose control and vascular complications in veterans with type 2 diabetes
Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808431 · Cited by 4,762 · cited 2×
“The Action to Control Cardiovascular Risk in Diabetes Study Group (ACCORD) trial (21) demonstrated increased mortality with intensive glycemic goals (A1C of 6.4%), the Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation (ADVANCE) trial (22) showed similar cardiovascular outcomes wi…”
InfluentialDormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129 · cited 1×
“A similar separation in glycemic control was noted in the PROspective pioglitAzone Clinical Trial In macroVascular Events (PROactive) study (18), in which the primary composite cardiovascular end point failed to reach significance between therapies, but the secondary composite end point did reach significance.”
ResultStamler, J., Vaccaro, O., Neaton, J. D., Wentworth, D., & The Multiple Risk Factor Intervention Trial Research Group (1993) · Diabetes Care · doi:10.2337/diacare.16.2.434 · Cited by 4,063
Diabetes and Atherosclerosis: Epidemiology, Pathophysiology, and Management
Beckman, J. A., Creager, M. A., & Libby, P. (2002) · JAMA · doi:10.1001/jama.287.19.2570 · Cited by 2,724
Chiasson, J.-L., Josse, R. G., Gomis, R., Hanefeld, M., Karasik, A., Laakso, M., & for The STOP-NIDDM Trial Research Group (2003) · JAMA · doi:10.1001/jama.290.4.486 · Cited by 1,624
Glucose Tolerance and Cardiovascular Mortality: Comparison of Fasting and 2-Hour Diagnostic Criteria
(2001) · Archives of Internal Medicine · doi:10.1001/archinte.161.3.397 · Cited by 1,371
Malmberg, K. (1997) · BMJ · doi:10.1136/bmj.314.7093.1512 · Cited by 1,286
Malmberg, K., Rydén, L., Wedel, H., Birkeland, K., Bootsma, A., Dickstein, K., Efendic, S., Fisher, M., Hamsten, A., Herlitz, J., et al. (2005) · European Heart Journal · doi:10.1093/eurheartj/ehi199 · Cited by 1,048
Postprandial Hyperglycemia and Diabetes Complications
Ceriello, A. (2005) · Diabetes · doi:10.2337/diabetes.54.1.1 · Cited by 945
Fasting and Postchallenge Glycemia and Cardiovascular Disease Risk
Meigs, J. B., Nathan, D. M., D’Agostino, R. B., & Wilson, P. W. F. (2002) · Diabetes Care · doi:10.2337/diacare.25.10.1845 · Cited by 509 · cited 1×
“There is strong epidemiological evidence that postchallenge/postprandial plasma glucose levels independently predict CVD events, and evidence that fasting plasma glucose levels are predictive is much weaker (8,9).”
BackgroundSelf-citationEsposito, K., Giugliano, D., Nappo, F., & Marfella, R. (2004) · Circulation · doi:10.1161/01.cir.0000134501.57864.66 · Cited by 440 · cited 2×
“Determination of sample size The details of the study sample size determination were published previously (14).”
BackgroundNunnelee, J. D. (2008) · Journal of Vascular Nursing · doi:10.1016/j.jvn.2008.08.002 · Cited by 407
Ceriello, A., Assaloni, R., Da Ros, R., Maier, A., Piconi, L., Quagliaro, L., Esposito, K., & Giugliano, D. (2005) · Circulation · doi:10.1161/01.cir.0000165070.46111.9f · Cited by 298 · cited 1×
“Some of these therapies may also counterbalance the adverse effects of postprandial glucose on oxidative stress (25).”
BackgroundJuutilainen, A., Lehto, S., Rönnemaa, T., Pyörälä, K., & Laakso, M. (2008) · Diabetes Care · doi:10.2337/dc07-2124 · Cited by 194
Impact of Incident Diabetes and Incident Nonfatal Cardiovascular Disease on 18-Year Mortality
Eberly, L. E., Cohen, J. D., Prineas, R., Yang, L., & For The Multiple Risk Factor Intervention Trial Research Group (2003) · Diabetes Care · doi:10.2337/diacare.26.3.848 · Cited by 149
Shimabukuro, M., Chinen, I., Higa, N., Takasu, N., Yamakawa, K., & Ueda, S. (2007) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/86.4.923 · Cited by 68 · cited 1×
“The postprandial hyperglycemia hypothesis has been supported by interventional studies demonstrating that reduced postprandial glycemia and lipids decrease inflammation and improve endothelial function (15) and are associated with a lesser degree of atherosclerotic progression (14,16,17).”
BackgroundMita, T., Watada, H., Shimizu, T., Tamura, Y., Sato, F., Watanabe, T., Choi, J. B., Hirose, T., Tanaka, Y., & Kawamori, R. (2007) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.107.152835 · Cited by 61 · cited 1×
“The postprandial hyperglycemia hypothesis has been supported by interventional studies demonstrating that reduced postprandial glycemia and lipids decrease inflammation and improve endothelial function (15) and are associated with a lesser degree of atherosclerotic progression (14,16,17).”
BackgroundMiličević, Z., Raz, I., Strojek, K., Škrha, J., Tan, M. H., Wyatt, J., Beattie, S. D., & Robbins, D. C. (2005) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2004.06.003 · Cited by 33 · cited 1×
“Study design and methodologies have been described previously (13).”
MethodSelf-citationAlssema, M., Schindhelm, R. K., Dekker, J. M., Diamant, M., Kostense, P. J., Teerlink, T., Scheffer, P. G., Nijpels, G., & Heine, R. J. (2007) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2006.12.021 · Cited by 23 · cited 1×
“The postprandial hyperglycemia hypothesis has been supported by interventional studies demonstrating that reduced postprandial glycemia and lipids decrease inflammation and improve endothelial function (15) and are associated with a lesser degree of atherosclerotic progression (14,16,17).”
BackgroundInsulin vs. strict blood glucose control to achieve a survival benefit after AMI?
den Berghe, G. V. (2005) · European Heart Journal · doi:10.1093/eurheartj/ehi232 · Cited by 22
Cited by
Cosentino, F., Grant, P. J., Aboyans, V., Bailey, C. J., Ceriello, A., Delgado, V., Federici, M., Filippatos, G., Grobbee, D. E., Hansen, T. B., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz486 · Cited by 4,763
Standards of medical care in diabetes—2014
American Diabetes Association (2014) · Diabetes Care · doi:10.2337/dc14-s014 · Cited by 4,572
“Additionally, an RCT in patients with known CVD found no CVD benefit of insulin regimens targeting postprandial glucose compared with those targeting preprandial glucose (102).”
BackgroundStandards of medical care in diabetes—2013
American Diabetes Association (2013) · Diabetes Care · doi:10.2337/dc13-s011 · Cited by 4,369
“Additionally, an RCT in patients with known CVD found no CVD benefit of insulin regimens targeting postprandial glucose compared with those targeting preprandial glucose (104).”
BackgroundStandards of medical care in diabetes 2010
American Diabetes Association (2010) · Diabetes Care · doi:10.2337/dc10-s011 · Cited by 3,470
Standards of medical care in diabetes—2011
American Diabetes Association (2011) · Diabetes Care · doi:10.2337/dc11-s011 · Cited by 2,880
Metadata
- Authors
- Raz, I., Wilson, P. W. F., Strojek, K., Kowalska, I., Bozikov, V., Gitt, A. K., Jermendy, G., Campaigne, B. N., Kerr, L., Milicevic, Z., & Jacober, S. J.
- Affiliations
- Hadassah Medical Center (IL)
- Emory University (US)
- Medical University of Silesia (PL)
- Medical University of Białystok (PL)
- Endocrinology, Diabetes and Metabolic Diseases, University Hospital Dubrava, Zagreb, Croatia
- Cardiology, Herzzentrum Ludwigshafen, Ludwigshafen, Germany
- Medical Department, Bajcsy-Zsilinszky Teaching Hospital, Budapest, Hungary
- Eli Lilly (United States) (US)
- Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2009-03-01
- Volume
- 32
- Issue
- 3
- Pages
- 381-386
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC2646013
- OpenAlex
- W2172111876
- Cited by
- 351
- References
- 26
- Citations by year
- 2025: 5 · 2024: 9 · 2023: 2 · 2022: 5 · 2021: 12 · 2020: 13 · 2019: 18 · 2018: 20 · 2017: 22 · 2016: 28 · 2015: 36 · 2014: 25 · 2013: 35 · 2012: 24
- FWCI
- 29.32
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company
- Sanofi
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Keywords
- type 2 diabetes, acute myocardial infarction, insulin lispro, basal insulin, postprandial blood glucose, glycemic excursions, cardiovascular outcomes, HbA1c, lack of efficacy
- MeSH terms
- Insulin Glargine, Adult, Aged, Body Weight, Cardiovascular System, Diabetes Mellitus, Type 2, Drug Administration Schedule, Fasting, Female, Humans, Hypoglycemic Agents, Insulin, Male, Middle Aged, Risk Factors, Treatment Outcome, Postprandial Period, Insulin, Long-Acting, Insulin Lispro
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.